Combination Immunotherapy Holds Promise for Patients with Rare Bladder Cancer

A woman recently came to Bradley McGregor, MD, an oncologist at Dana-Farber Cancer Institute, in severe pain with extreme fatigue. Her squamous cell bladder cancer, a rare type for which traditional treatment is generally less effective, had advanced, and it appeared that she had no other options. But timing is everything. McGregor was conducting a … Read more

The Latest Efforts in Precision Oncology for Advanced Prostate Cancer

The management of advanced prostate cancer is rapidly evolving with the application of precision treatments based on genomic testing of tumors’ altered DNA. With recent biomarker-driven drug approvals and increased clinical use of genomic testing, there are a number of opportunities to expand upon this framework. Researchers are calling for increased collaboration and new strategies. … Read more

The Latest on Dana-Farber AIDS/HIV Research

The development of antiviral drug “cocktails” for AIDS in the mid-1990s has saved and extended the lives of millions of people around the world, but much more work is needed before the disease is truly vanquished. Despite significant advances in treatment and expanded efforts to slow the spread of the disease, AIDS remains a global … Read more

Study Identifies Genes That Help Drive Growth in Melanoma Subtypes

Favoritism or impartiality? Do the four genomic subtypes of melanoma have a bias toward certain mutated genes and gene pathways, or do they welcome all mutations equally? Answering that question has been especially difficult because of cutaneous melanoma’s high mutation rate — the profusion of misspelled, severed, out-of-place, missing-in-action, or overabundant genes found in melanoma … Read more

Drugs Targeting a Pathway in Glioblastoma Must Clear a High Bar, Study Suggests

Researchers had every reason to expect that a compound called BKM120 (also known as buparlisib) would stifle glioblastoma brain tumors lacking the protein PTEN. After all, it was known to block the tumor-promoting PI3K protein and could easily pass through the blood-brain barrier — the dense layer of cells that guards entry to the brain … Read more

Venetoclax Combination Approved for Older Patients with AML

The U.S. Food and Drug Administration (FDA) approved a novel targeted drug to treat acute myelogenous leukemia (AML) in older patients, a segment of the blood cancer population in dire need of improved therapies. In a phase 3 clinical trial, researchers showed that the oral drug, venetoclax (or Venclexta), when given along with azacitidine, could … Read more

Cancer Prevention and Care Resources for Marginalized Patients and Advocates

Cancer does not affect everyone in the same way. A combination of factors, including race, ethnicity, sexual orientation, or socioeconomic status can make some patients face a greater cancer burden and poorer outcomes in cancer care and treatment. These inequities are called cancer disparities. The causes “are complex and reflect social and economic disparities and … Read more

Biomarker Search Reveals Unexpected Associations in Treatment of Advanced Kidney Cancer

Scientists are gratified when a clinical trial reveals whether one treatment — often an experimental therapy or drug combination — is superior to another. But researchers then often look more deeply into the data, searching for characteristics of tumors associated with a treatment’s effectiveness, or lack of it. In today’s world of precision medicine, identifying … Read more

What are Cancer Disparities and How Are Dana-Farber Researchers Addressing Them?

Despite enormous advances in cancer treatment, some racial, ethnic, and socioeconomic groups still bear an especially large burden from the disease, with higher incidence rates for many cancers and poorer outcomes. Decades of research has documented these disparities. Among adult patients, for example, African Americans have the highest mortality rate of any racial or ethnic … Read more

Study Identifies Candidate Combinations for Triple-Negative Breast Cancer

In their quest for effective targeted therapies to treat triple-negative breast cancer (TNBC) — an aggressive disease that often doesn’t respond to standard chemotherapy — researchers at Dana-Farber and elsewhere have recently focused on the potential of drugs known as BET bromodomain inhibitors. BET inhibitors target a family of proteins including BRD2, BRD3, BRD4, and … Read more

Diving Into Ependymomas, Hard-to-Treat Pediatric Brain Tumors

Ependymomas are some of the most difficult-to-treat brain tumors. Mariella Filbin, MD, PhD, a neuro-oncologist at Dana-Farber/Boston Children’s Cancer and Blood Disorders Center, is driven by a desire to find new therapies for these pediatric brain tumors. At the core of her work is an effort to uncover the events that shape tumor development. Defining how … Read more

New Drug Regimens Show Promise in Early and Late Myeloma

Treatment advances for multiple myeloma continue to bring improved outcomes for patients in different stages of their disease. Recent clinical trial reports show progress in treating two myeloma populations — newly diagnosed, transplant eligible patients, and individuals whose disease has progressed following several lines of therapy. In one trial, the phase 2 GRIFFIN study showed … Read more

Study Finds New Vulnerabilities in Diabetes-Associated Liver Cancer

Liver cancer that develops in people with obesity and Type 2 diabetes is dependent on elevated amounts of a protein that might be targeted for treatment by two existing drugs, say Dana-Farber scientists. The research reported in Cancer Research by Pere Puigserver, PhD, and colleagues pertains specifically to liver cancer in individuals who are obese … Read more

Wave of New Therapies Improve Outcomes for Patients with Multiple Myeloma

For many patients with multiple myeloma, a new generation of drugs and drug combinations is producing better outcomes and fewer side effects. In recent months, several novel therapies studied and tested by Dana-Farber scientists have gained approval from the U.S. Food and Drug Administration (FDA) or taken a step toward approval after posting solid results … Read more

Institute Researchers Take Lead in Trials of Potential COVID-19 Therapies

Insights from decades of cancer research are surprisingly transferable to the battle against COVID-19. The desire to save life and ease suffering that motivates cancer researchers has been directed to the new disease as well. Drawing on their knowledge of cancer drug mechanisms, and of the adverse side effects of some of those drugs, Dana-Farber … Read more